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  INTRODUCTION 
 
 Diabetes Mellitus is a major health hazard today. 
According to World Health Organization, at least 177 million people 
worldwide suffer from diabetes. It is estimated that there will be rapid 
increase in the number of persons with diabetes mellitus worldwide. 
In India, the number shall be 57 million by 2025, compared with 19 
million in 1995. 
     Diabetic retinopathy remains a leading cause of blindness in the 
world in the age group of 20 to 75 years. Blindness in diabetic 
retinopathy results from non resolving vitreous hemorrhage, tractional 
retinal detachment or diabetic macular edema. 
     As the severity of overall retinopathy increases, the proportion of 
eyes with macular edema also increases- 30% in mild NPDR, 38% in 
moderate to severe NPDR and 71% in PDR. 
    Diabetic maculopathy is a term that encompasses a wide range of 
intra retinal and pre retinal pathological changes affecting the macula 
in diabetic retinopathy. The intra retinal changes are composed of two 
distinct but inter related components: 
  
1. Retinal ischemia due to capillary and arteriolar non perfusion. 
2. Retinal edema due to breakdown in the blood retinal barrier. 
Diabetic macular edema may be present at any level of retinopathy 
and alter the structure of macula, significantly affecting its function.     
    The two major categories of macular edema in diabetic 
maculopathy are focal macular edema and diffuse macular edema. 
Focal macular edema is characterized by areas of focal 
fluorescein leakage from specific capillary lesions like micro 
aneurysms, dilated capillary segments and is often associated with 
hard exudates rings. 
Diffuse macular edema presents a much more complex problem 
than focal macular edema. It is characterized by widespread retinal 
capillary abnormalities associated with diffuse leakage due to 
extensive breakdown of blood retinal barrier throughout the posterior 
pole and often formation of cystoid macular edema. 
Effects of diabetes on macula: 
1. Macular edema- collection of intra retinal fluid in macula with 
or without lipid exudation and cystoid changes. 
2. Traction in macula by fibrous tissue proliferation causing a 
dragging of retinal tissue, surface wrinkling or detachment of 
macula. 
2. Intra retinal or pre retinal hemorrhage at macula. 
3. Lamellar or full thickness retinal hole formation. 
          Clinically, macular edema is retinal thickening within two disc 
diameters from centre of the macula.  
Clinically significant macular edema(CSME), as defined by the 
ETDRS, includes any one of the following lesions: 
1. Thickening of retina located within 500 u from centre of 
macula or 
2. Hard exudates with thickening of adjacent retina located 
within 500 u from centre of macula or 
3. A zone of retinal thickening, one disc area or larger in size, 
located within one disc diameter from centre of macula. 
Most patients with DME experience blurred vision, but patients 
without involvement of centre of macula may have excellent visual 
acuity and no visual complaints. Once DME develops, treatment is 
more likely to stabilize vision than to improve it. Hence, it is 
important to examine asymptomatic diabetic patients regularly 
rather than waiting for visual loss to occur, at which time the 
condition may be more advanced and less responsive to treatment. 
 There are particular retinal lesions identified on FFA that are 
amenable to treatment. These ‘treatable lesions’ associated with 
macular edema include- 
a) Focal leaks > 500 u from centre of macula believed to be 
causing retinal thickening or hard exudates. 
b) Focal leaks 300–500 u from the centre of macula believed 
to be causing retinal thickening or hard exudates, if the 
ophthalmologist does not believe that treatment is likely 
to destroy the remaining perifoveal capillary network. 
c) Areas of diffuse leakage that have not been treated 
previously. 
d) Avascular zones, other than ‘FAZ’ not treated previously 
The ETDRS used 2 types of photo coagulation treatment for 
DME, focal and grid.  Focal refers to direct treatment of all leaking 
micro aneurysms in the edematous retina, b/w 500-3000u from the 
centre of macula.   
Grid treatment is used primarily for identifiable focal leakage 
areas and thickened avascular zones. 
Elevated lipid levels are associated with endothelial 
dysfunction, which appears to play an important role in the 
pathogenesis of DR, particularly in relation to break down of blood 
retinal barrier and development of CSME and hard exudates. Patients 
with diabetes are known to have severe lipid abnormalities like hyper 
cholesterolemia and elevated serum triglycerides. The WESDR, a 
population based study and the ETDRS found that increased levels of 
serum cholesterol were associated with increased severity of hard 
exudates in retina.  Independent of accompanying macular edema, the 
severity of retinal hard exudates at base line was associated with 
decreased visual acuity in the ETDRS. The severity of retinal hard 
exudates also was a significant risk factor for moderate vision loss 
during the course of the study. The data are compelling to recommend 
lowering raised serum lipid levels in patients with DR to reduce the 
risk of visual loss besides reducing the risk of cardiovascular disease.  
However, to our knowledge there is no case control study that has 
compared the lipid profile levels in subjects with and without CSME.   
 
 
 
                            DIABETES IN A NUTSHELL 
 
Diabetes Mellitus (DM) is a chronic condition that occurs when 
the pancreas does not produce enough insulin or when the body 
cannot effectively use the insulin it produces. 
 
Hyperglycemia and related disturbances in the body’s 
metabolism can lead to serious damage of many systems especially 
the nerves and blood vessels.  
There are 2 basic forms of DM 
1. Type 1 - People with this type of DM produce very little or 
no insulin. They require daily injections of insulin to survive. 
2. Type -2 - People of this type of DM cannot use insulin 
effectively. This condition can sometimes be managed with 
life style measures alone but oral drugs are often required 
and less frequently insulin in order to achieve good 
metabolic control. 
Most people have type 2 DM. Many are symptomless and only 
diagnosed after many years of onset. 
 
PATHOGENESIS OF DIABETIC RETINOPATHY 
Diabetic retinopathy is a micro angiopathy primarily affecting 
the pre capillary arterioles, capillaries and post capillary venules, 
although larger vessels may also be involved. It exhibits features of 
both micro vascular occlusion and leakage. 
A. Micro vascular occlusion 
Pathogenesis: 
1. Capillary occlusion: Consists of loss of pericytes, thickening of 
basement membrane and damage and proliferation of 
endothelial cells. 
2. Hematological changes: consists of deformation and rouleaux 
formation of red blood cells and increased platelet stickiness 
and aggregation, leading to decreased oxygen transport. 
Consequence:  
     Retinal capillary non perfusion leads to retinal ischemia. The 
effects of this are  
1. Arterio venous shunts  
2. Neo vascularisation 
 
 
B. Micro vascular leakage 
 Pathogenesis:  
Breakdown of inner blood retinal barrier leads to leakage of 
plasma constituents into the retina. Micro aneurysms which are due to 
physical weakening of the capillary wall are formed, which may leak 
or get thrombosed.  
Consequence: 
Increased vascular leakage leads to development of  
1. Intra retinal hemorrhages  
2. Diffuse retinal edema 
3. Localized retinal edema. 
 
 
 
 
 
 
 
 
 
CLASSIFICATION OF DIABETIC RETINOPATHY 
1. NON PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) 
a. Mild NPDR: Micro aneurysms plus retinal hemorrhages, hard 
exudates. 
b. Moderate NPDR: Mild NPDR plus cotton wool spots and/or 
IRMA. 
c. Severe NPDR: Presence of one of the following features. 
i. Micro aneurysms plus venous beading and/or 
hemorrhage/ Micro aneurysms > standard photograph 2A 
in four quadrants. 
ii. Marked venous beading in two or more quadrants. 
iii. Moderate intra retinal micro vascular anomalies (Standard 
photographs 8) one or more quadrant. 
d. Very severe NPDR: Two or more of the features described in 
severe NPDR. 
2. PROLIFERATIVE DIABETIC RETINOPATHY (PDR) 
a. PDR without high risk characteristics  
 New vessels and/or fibrous proliferation; or pre retinal 
and/or vitreous hemorrhage. 
b. PDR with high risk characteristics  
NVD > standard photograph 10A; or less extensive NVD 
if vitreous or pre retinal hemorrhage is present; or NVE > 
half disc area; if vitreous or pre hemorrhages are present. 
          c.   Advanced PDR  
 Extensive vitreous hemorrhage precluding grading, retinal       
detachment involving the macula, phthisis bulbi or enucleation 
secondary to a complication of secondary retinopathy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RISK FACTORS FOR THE PROGRESSION OF DIABETIC 
RETINOPATHY 
1. Duration of Diabetes : 
 The best predictor of diabetic retinopathy is the duration of the 
disease.  Patients who have had type 1 for 5 years or less rarely show 
any evidence of diabetic retinopathy. However, 27% of those who 
have had diabetes for 5-10 years and 71-90% of those who had 
diabetes for longer than 10 years have diabetic retinopathy. After 20 
years, the incidence rises to 95%, and about 30-50% of these patients 
have proliferative diabetic retinopathy. 
 Yanko et al described the prevalence of retinopathy in patients 
with type 2 diabetes. They found that the prevalence of retinopathy 
11-13 years after the onset of diabetes was 23%, after 16 or more 
years, it was 60% and 11 or more years after the onset, 3% of the 
patients had PDR. 
 Klein et al found that 10 year after the diagnosis of type 2 
diabetes, 67% of patients had retinopathy and 10% had PDR. 
2. Effect of control of blood glucose: 
 The Diabetes Complications and Control Trial (DCCT) showed 
that patients with type 1 diabetes who had tight blood glucose control 
do far better than patients treated with conventional therapy.  The 
former had a 76% reduction in the rate of development of any 
retinopathy and a 54% reduction in progression of established 
retinopathy as compared with the conventional treatment group. For 
advanced retinopathy, however, even the most rigorous control of 
blood glucose may not prevent progression.  The value of intensive 
treatment has been demonstrated in patients with type 2 diabetes as 
well. 
3. Presence of renal disease: 
 Renal disease is an excellent predictor of the presence of 
retinopathy.  Even patients with micro albuminuria are at high risk of 
developing retinopathy.  Similarly, 35% of patients with symptomatic 
retinopathy show evidence of renal disease. 
 
4.  Hypertension: 
 Systemic hypertension appears to be an independents risk factor 
for diabetic retinopathy. Tight control appears to be particularly 
beneficial in type 2 diabetes with maculopathy. A study by 
Chaturvedi et al suggested that there might be a specific benefit of 
angiotensin converting enzyme inhibition and blood pressure 
reduction on the progression of diabetic retinopathy. 
5. Elevated serum lipid levels: 
         The WESDR and the ETDRS found that elevated levels of 
serum cholesterol were associated with increased severity of retinal 
hard exudates. Elevated levels of serum triglycerides and LDL-C 
were found to be associated with greater risk of developing PDR. 
 
6. Pregnancy: 
 Diabetic retinopathy may be accelerated during pregnancy 
because of pregnancy itself or the changes in metabolic control.  
Fortunately, there is usually some regression after delivery.  The risk 
of developing NPDR is about 10% and 4% of patients with NPDR 
progress to PDR. 
 
7. Other systemic risk factors: 
 Anemia has been reported to be associated with progression of 
diabetic retinopathy. 
 History of diabetic neuropathy and cardiovascular autonomic 
neuropathy has also been suggested to be associated with increased 
risk of progression of retinopathy. 
 
TREATMENT OF DIABETIC MACULAR EDEMA (DME) 
 
DME is the most common cause of moderate to severe visual 
loss in patients with diabetic retinopathy. The ETDRS proved that 
laser treatment reduces moderate visual loss in patients with CSME. 
Among the ETDRS, in patients with CSME, 33% who were 
randomized to no treatment had visual loss after 3 years follow up. 
Focal treatment reduced this frequency by 60% to 13%. CSME 
requires laser photo coagulation irrespective of visual acuity because 
treatment reduces the loss of vision loss by 50%.  
Mechanism of action of laser in DME: 
1. Focal burns appear to coagulate the leaking micro aneurysms or    
the retinal vessels in the inner and middle retina which cause DME 
They stop leaking and result in improvement in DME.  
2. Damage to the outer blood retinal barrier causes the elaboration of 
a substance that in turn, causes mitosis of endothelial cells. After 
treatment, the vessels leak less and/or absorb more affecting a 
reduction of DME and accompanying hard exudates.  
3. Laser treatment destroys some of the photo receptors and retinal 
pigment epithelial cells which are the layers which consume most of 
the oxygen used by the retina. Post treatment scarring also causes 
retinal thinning which allows for better diffusion of oxygen from the 
choroids. After laser treatment, oxygen consumption of the retina is 
reduced and the supply to thin retina from the choroid is increased. 
4. Retinal capillaries, especially in patients with severe DME, are 
often dilated before treatment and become narrower and less leaky 
after laser treatment. 
The techniques of laser treatments in DME are: 
a. Focal treatment: Involves application of laser burns to the 
micro aneurysms and micro vascular lesions in the centre of 
rings of hard exudates located 500 to 3000 micrometers from 
the centre of the macula. The spot size is 50-100 micrometers 
and exposure time of 0.1 seconds with sufficient power to 
obtain gentle whitening or darkening of the lesions. Treatment 
up to 300 micrometers from the centre of the macula may be 
considered if CSME persists despite previous treatment and 
visual acuity is < 6/12. In these cases a shorter exposure time of 
0.01 seconds is recommended. 
b. Grid treatment: It is used for areas of diffuse retinal thickening 
located more than 500 micrometers from the centre of the 
macula and 500 micrometer from temporal margin of the optic 
disc. The spot size is 100 micrometers and exposure is 0.1 
second giving a very light intensity burn and one burn width 
apart.  
Approximately 70% of eyes achieve stable visual acuity, 15% 
show improvement and 15% subsequently deteriorate. Since it may 
take up to four months for the edema to resolve, retreatment should 
not be considered prematurely.  
Other forms of treatment: 
1. Pars Plana Vitrectomy may be indicated when macular edema is 
associated with tangential traction from a thickened and taut 
posterior hyaloid. In these cases, laser is of limited benefit but 
surgical release of traction may be beneficial. OCT is invaluable 
in demonstrating eyes with marked vitreoretinal traction that 
may benefit most from surgery.  
2. Intra vitreal triamcinalone acetonide may be tried for the 
treatment of diffuse macular edema that fails to respond to 
conventional laser photocoagulation. Its complications include 
endophthalmitis, intra ocular hemorrhage, retinal detachment 
and increased intra ocular pressure. The therapeutic effect fades 
after six months and macular edema frequently returns. 
3. Posterior subtenon triamcinalone acetonide may improve visual 
outcome in diffuse macular edema when combined with laser 
photo coagulation but long term results are lacking.  
4. Anti VEGF agents are also under study for treatment of DME .  
5. Hypo lipidemic drugs have been shown to reduce the severity  
of hard exudates and sub foveal lipid migration in eyes with 
CSME in type 2 diabetes mellitus patients with dyslipidemia 
and may become an important therapeutic adjunct.  
 
 
 
 
 
 
 
 
 
 
 
 
OVERVIEW OF LIPIDS 
Lipids are a heterogeneous group of water insoluble organic 
molecules that can be extracted from tissues by non polar solvents. 
Due to their insolubility in aqueous solutions, body lipids are 
generally found either compartmentalized, as in case of membrane 
associated lipids and droplets of tryglycerides in adipocytes, or 
transported throughout the body in association with proteins as 
lipoprotein particles. These particles include chylomicrons , very low 
density lipoprotein(VLDL) , low density lipoprotein(LDL) and high 
density lipoprotein(HDL). 
 Lipoproteins are spherical particles made up of hundreds of 
lipid and protein molecules, smaller than RBC’s are seen only by 
electron microscope. Major lipids present in lipoproteins are 
cholesterol, triglycerides and phospholipids. Triglycerides and the 
esterified form of cholesterol (Cholesteryl ester) are non polar and 
hydrophobic and comprise the lipoprotein core. Phospholipids and 
small quantities of free cholesterol which are soluble in both aqueous 
and lipid envelop (amphipathic) cover the surface of the particle, 
where they act as interface between plasma and core components. 
 A very important lipid is cholesterol. It is an alicyclic 
compound whose structure includes basically a 
perhydrocyclopentenophenantheren nucleus with its four fused rings. 
Cholesterol has very low solubility in water. The actual concentration 
of cholesterol in the plasma of healthy people is usually 150-
200mg/dl. The very high solubility of cholesterol in blood is due to 
proteins called plasma lipoproteins (mainly LDL and VLDL) that 
have the ability to bind and thereby solubilise large amounts of 
cholesterol. 
 Only 30% of total circulation cholesterol occurs free as such, 
around 70% of the cholesterol in plasma lipoproteins exist in the form 
of cholesterol esters. 
 Cholesterol is abundant in bile. Solubilisation of free 
cholesterol in bile is achieved by the detergent property of the 
phospholipids present in bile that are produced in the liver. 
 Cholesterol, which can be derived from diet are manufactured 
de novo in virtually all human cells plays very important role. It is a 
major sterol in virtually all plasma and intra cellular membranes. It is 
especially abundant in the myelinated structures of the brain and the 
CNS. Most of the cholesterol in cellular membranes occurs in free 
form. It is the immediate precursor of bile acids, that are synthesized 
in the liver and that function to facilitate the absorption of dietary 
triglycerides and fat soluble vitamins. It is also the precursor of 
various steroid hormones.  
 Cholesterol biosynthesis is carefully regulated. When dietary 
cholesterol is reduced, cholesterol synthesis is increased in liver and 
intestine. Cholesterol synthesized de novo is transported from liver 
and intestine to peripheral tissues in the form of lipoproteins. Only 
these two tissues can manufacture apolipoprotein D, the protein 
component of cholesterol transport proteins LDL and VLDL. Highest 
proportion of cholesterol is found in LDL. Most of the apo B is 
secreted into the circulation as VLDL, which is converted in LDL but 
removal of triglycerol and the apo C components, probably in 
peripheral tissues and liver. In contrast when the quantity of dietary 
cholesterol increases, synthesis is almost totally suppressed. 
 Virtually all tissues containing nucleated cells are capable of 
synthesizing cholesterol. Synthesis takes place in several stages. The 
primary site for control of cholesterol biosynthesis is HMG COA 
reductase, which catalyses the step that produces mevalonic acid. This 
is a committed step and the rate limiting reaction in the pathway of 
cholesterol biosynthesis. 
HYPERLIPOPROTEINEMIAS: 
    Broadly classified as: 
1. Isolated hypercholesterolemia: 
Increased levels of fasting total plasma cholesterol, in presence 
of normal levels of triglycerides, is almost always associated 
with increased levels of plasma LDL-C(type II a ) as LDL 
carries 65-75% of total cholesterol. 
 
2. Isolated triglyceridemia: 
The diagnosis of hypertriglyceridemia is made by determining 
levels of plasma lipids after an overnight fast. Isolated elevation 
of plasma triglycerides can be due to increased levels of VLDL 
(type 4) or a combination of VLDL and chylomicrons (type 5 )  
 
3. Hypertriglyceridemia and Hypercholesterolemia 
Combination of the conditions can also occur. 
 
 
Classification of Total cholesterol, LDL Cholesterol and HDL  
Cholesterol values: 
 Total cholesterol        LDL-C        HDL-C 
Desirable 5.2 mmol/l <3.36 mmol/l >1.55 mmol/l 
 <200 mg/dl <130 mg/dl >60 mg/dl 
Borderline 5.5-6.18 
mmol/dl 
3.36-4.14 
mmol/dl 
0.9-1.55 
mmol/dl 
 200-239 mg/dl 130-159 mg/dl 35-60 mg/dl 
Undesirable >6.21 mmol/l >4.41 mmol/l <0.9 mmol/l 
 >240 mg/dl >160 mg/dl <35 mg/dl 
 
    The correlation between high levels of blood cholesterol, 
particularly LDL cholesterol and heart attacks and strokes have led to 
the development of dietary and therapeutic approaches to lower blood 
cholesterol. 
Treatment of dyslipidemias: 
Non Pharmacological Treatment : 
 Diet and dietary modification is an important component in the 
management of dyslipidemias.  The physician should assess the 
content of the patient’s diet and provide suggestions for dietary 
modification. Other modifications of lifestyle include cessation of 
smoking, cutting down alcohol intake, weight reduction if appropriate 
and regular exercises. 
 
Pharmacological Treatment : 
1. HMG COA reductase inhibitors (statins): HMG COA reductase 
in the rate limiting step in cholesterol biosynthesis and inhibitors of 
this enzyme decreased cholesterol synthesis.  It causes dose 
dependent reduction in plasma levels of LDL & TGs and increase in 
HDL.  Statins are remarkably safe and well tolerated.  Potential side 
effects include dyspepsia, headache, fatigue muscle or joint pain and 
rarely severe myopathy and rhabdomyolysis. 
 Eg. Lovastatin, Provastatin, Snvastatin, Fluvaslatin, 
Atorvastatin, Rosuvastatin. 
 
2.  Cholesterol absorption inhibitors: 
 Ezetisube is a cholesterol absorption inhibitor that binds directly 
to a protein NPC ILI and blocks the intestinal absorption of 
cholesterol. It has been shown to decreased cholesterol also by almost 
60%.  It can be used in combination with statins.  
3. Bile Acid sequestrants (Resins) :  BAS 
 Bind bile acids in the intestine and promote their excretion. To 
maintain bile acid pool size, the liver diverts cholesterol to bile acid 
synthesis. 
 Eg.  Cholestyramine, colestipol, colesevelam 
4. Nicotinic Acid (Niacin): 
 Niacin is a lipid modifying agents with decreased plasma TG 
and LDL levels and increased HDL – C.  It is also the only currently 
available lipid lowering agent that significantly reduces plasma levels 
of LP(a) 
5. Fibric acid derivatives (Fibrates): 
 FAD are agonists of PPAR alpha, a nuclear receptor involved in 
the regulation of carbohydrate and lipid metabolism. Fibrates are the 
most effective drugs available for reducing TG, VLDL and increased 
HDL C 
6.  Omega 3 Fatty Acids (Fish oils) 
 Polyunsaturated fatty acids are present in high concentrations in 
fish and in flax seeds, Low dose of Omega 3 has been also decreased 
fasting TG levels and reduction in cardiovascular events in CHD 
patients. 
REVIEW OF LITERATURE 
 
There are conflicting reports in literature regarding the lipid 
profile in diabetics. Some workers have found elevated levels of 
cholesterol and no difference was observed in serum phospholipids 
between diabetics with and without retinopathy. Lopes – Virella et al 
found inverse correlation between HDL-C with poorly controlled 
diabetics. Few reports suggest that there is significant increase in 
cholesterol, phospholipids and triglycerides in diabetics with 
retinopathy as compared to controls.   
Emily. Y. Chew et al studied observational data from ETDRS 
and evaluated the relationship between serum lipid levels, retinal hard 
exudates and visual acuity in patients with diabetic retinopathy. They 
concluded that patients with elevated total serum cholesterol levels 
and serum LDL-C at baseline where twice as likely to have retinal 
hard exudates as patients with normal levels. The risk of losing visual 
acuity was associated with the extent of hard exudates. The 
observational data from ETDRS suggest that lipid lowering may also 
decrease the risk of hard exudates formation and associated visual 
loss in patients with diabetic retinopathy. 
Barbara.E.Klein et al did a study of the cohort of younger onset 
diabetes mellitus group in Wisconsin Epidemiologic Study of 
Diabetic Retinopathy (WESDR) to determine whether relationship 
exists among the serum lipid levels and severity of diabetic 
retinopathy, retinal hard exudates and macular edema 5 years later. 
Their data suggested that lowering cholesterol levels by diet or 
pharmacological means was not indicated for the sole purpose of 
reducing the incidence or severity of retinal lesions. 
Klein R, Klein B.E.K et al measured serum total and HDL-
Cholesterol in a sample of individual in WESDR. It showed a 
significant trend for increasing severity of diabetic retinopathy and of 
retinal hard exudates with increasing cholesterol in insulin using 
persons. However, no relationship was found between total 
cholesterol and severity of hard exudates in the older onset group that 
did not use insulin. They concluded that different pathogenic 
mechanisms may be associated with the development of hard 
exudates in people who have different type of diabetics. 
S.P.Dhir, Rajvir Dahiya et al in a study done in North India of 
the lipoprotein profile in diabetic patients with and without diabetic 
retinopathy did not reveal any significant difference though all the 
values were slightly elevated in diabetic retinopathy group as 
compared to diabetics without retinopathy.   
       A number of recent cross sectional studies suggest that serum 
lipids may have a causative role in macular exudates. Comparison of 
a small group of diabetic patients with severe exudative maculopathy 
to a group of non exudates retinopathy by Brown GC et al 
demonstrated significantly higher levels of triglycerides in the formal 
group, although serum cholesterol was not significantly different. A 
case control study by Dodson PM et al where patients were matched 
for age, gender, glycemic control, duration and treatment of diabetes 
mellitus, found a trend for patients with maculopathy to have higher 
serum lipids over seven years follow up than patients without. An 
elevation in cholesterol has been shown in study of exudative 
maculopathy in type 1 diabetes mellitus by Miccoli R et al.  
      Further studies have linked LDL-Cholesterol with maculopathy, 
although number of patients in these studies has been small. A direct 
toxic effect of LDL on retinal capillary pericytes has also been 
demonstrated, and this toxic effect can be enhanced by LDL glycation 
or oxidation. In other small cross sectional studies, lipoprotein (a) has 
been suggested as a risk factor for maculopathy, although this finding 
was refuted on examination of a small subset of the WESDR 
population. Improved outcome following laser photo coagulation 
therapy for macular edema has been reported in subjects who have 
higher HDL-C or normal total cholesterol by Kremser BG et al. 
The role of dietary fat intake and its influence on exudative 
maculopathy has been examined. Ernst et al reported reduction in 
retinal exudates in eight diabetic patients after 2-3 years of 
carbohydrate rich, fat poor diet. Seven year follow up of the cohort of 
149 patients randomized to a low carbohydrate or a modified fat diet 
showed that patients with low levels linoleic in cholesterol ester had 
greater risk of retinopathy. 
Stronger evidence for a role of serum lipids in exudative 
maculopathy is suggested in prospective studies. In the ETDRS a 
study group of patients had serum lipid measured. Higher baseline 
total and LDL-C levels increased the risk of retinal exudation by two 
fold. On multivariate analysis, risk of losing visual acuity was 
associated with severity of hard exudation. In further analyses, 
increased serum cholesterol at baseline increased the risk of visual 
loss by 50% compared to lower serum cholesterol levels. These 
findings have been supported by examination of a sub group of the 
WESDR cohort. Increased total cholesterol was noted in patients with 
increased severity of retinopathy and hard exudates.  
Lipid lowering therapy in exudative maculopathy: 
Trials of clofibrate and atromid in exudative maculopathy have 
suggested that a reduction in macular hard exudates could be 
achieved, but with little improvement in visual acuity. Of note, 
however, is that the visual acuity of the patients in these trials was 
poor at the outset , and hence a significant improvement with lipid 
lowering therapy may not be expected. A more recent German pilot 
study used etofibrate in patients with type 2 diabetes and type 2b 
hyperlipoproteinemia with diabetic maculopathy. Clear regression of 
macular exudates was seen in seven of ten patients in six months. 
Two small pilot studies have used statin therapy in diabetic 
retinopathy. In one pilot study six patients with exudative 
maculopathy were treated with pravastatin which lowered their total 
and LDL cholesterol by 40%. Over one year, an improvement in hard 
exudates was seen in all patients, with decreased micro aneurysms in 
four patients was observed and visual acuity improved in one patient.   
 
 
 AIMS AND OBJECTIVES 
 
AIM OF THE STUDY: 
 The aim of this study is to compare the serum lipid profile in 
patients with diabetic retinopathy with clinically significant macular 
edema and without clinically significant macular edema. 
 
OBJECTIVES: 
1. To study the serum lipid profile in patients with diabetic 
retinopathy. 
2. To compare the serum lipid profile of patients with and without 
clinically significant macular edema. 
3. To compare and analyse the present study with reference to 
other studies on serum lipid profile in diabetic retinopathy. 
4. To emphasize the importance of doing serum lipid profile as a 
routine investigation in patients with diabetic retinopathy. 
 
 
 
MATERIALS AND METHODS 
The study group: 
 The study was conducted on patients with diabetic retinopathy 
visiting department of ophthalmology at Government Rajaji Hospital, 
Madurai. 
Period of Study: 
 The study was conducted for a period of one year from June 
2008 to May 2009.  
Inclusion Criteria: 
 Patients with diabetic retinopathy who are willing to participate 
in the study and have given consent to undergo blood tests for serum 
lipid levels and renal parameters. 
Exclusion Criteria: 
1. Patients who have had treatment for diabetic retinopathy 
2. Patients on treatment for dyslipidemias. 
3. Patients not willing to participate in the study. 
Sample size: 
 100 patients divided in to two groups of 50 each. 
Group A:  Patients with diabetic retinopathy with clinically 
significant macular edema. 
Group B:  Patients with diabetic retinopathy without clinically     
significant macular edema. 
Selection of study subjects: 
 Fifty consecutive patients each of Group A and Group B 
presenting to ophthalmology outpatient department and those referred 
from other departments with diabetic retinopathy fulfilling the 
inclusion criteria of the study. 
Methods: 
 A detailed history was elicited from the patient about the 
duration of diabetes mellitus, history of treatment, presence of other 
systemic conditions like hypertension and renal disease. 
 Anterior segment evaluation was done by slit lamp 
examination. After dilatation of the pupil with tropicamide eye drops, 
fundus examination was done using direct ophthalmoscopy, indirect 
ophthalmoscopy and slit lamp biomicroscopy with +90D lens.  
Appropriate fundus photographs were taken. Diabetic retinopathy was 
classified according to ETDRS classification. 
 All patients were advised overnight fasting and blood sample 
was taken for estimation of fasting blood glucose, serum lipid levels, 
blood urea and serum creatinine.  Systolic and Diastolic Blood 
pressure were measured in sitting posture. 
 Total cholesterol levels in serum were measured using 
Libermann Burchard reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND OBSERVATIONS 
Group A :      Patients with clinically significant macular edema 
Group B :      Patients without clinically significant macular edema 
Table -1:  Age Distribution of Cases 
Age groups 
(in years) 
Group A Group B 
No. Percentage No. Percentage 
Up to 50 yrs 9 18 8 16 
51 -60 21 42 23 46 
61 – 70 13 26 16 32 
> 70 7 14 3 6 
Total 50 100 50 100 
Range 
Mean 
S.D 
39 – 87  yrs 
59.7 yrs 
9.7 
42 – 77 yrs 
58.8 yrs 
7.8 
P 0.6762 Not significant 
 
                The age of the patients in the study ranged from 39- 87 years.  
Patients with CSME had mean age of 59.7 yrs and without CSME 58.8.  
Age was not found to be significantly related to the presence of CSME. 
 
  
 
Table -2:  Sex Distribution of Cases 
Sex Group A Group B 
No. Percentage No. Percentage 
Male 26 52 24 48 
Female 24 48 26 52 
Total 50 100 50 100 
P 0.8415 Not significant 
 
 Males slightly predominated the group with CSME with 52% and 
females in the group without CSME. 
 
 
 
 
 
 
 
 
 
  
 
Table -3:  Duration of DM 
Duration of DM 
(in years) 
Group A Group B 
No. Percentage No. Percentage 
Newly detected 6 12 8 16 
Up to 5 years 13 26 32 64 
6 – 10 years 10 20 6 12 
11 – 15 years 14 28 2 4 
>  15 years 7 14 2 4 
Total 50 100 50 100 
P value (< 10 yrs 
to > 10yrs) 
0.0002 Significant 
 
 Up to 28% of the patients with CSME had type 2 Diabetes Mellitus 
for duration ranging from 11-15 yrs whereas majority of the patients 
without CSME had Diabetes Mellitus for up to 5 years comprising 64% of 
the total. 
 
 
  
 
 
    Table -4:  Drugs 
Drugs Group A Group B 
No. Percentage No. Percentage 
Yes 39 78 35 70 
No 11 22 15 30 
P 0.494 Not significant 
 
 Among the patients with CSME, 78% were on treatment and 70% 
among the patients without CSME were on treatment for Diabetes 
Mellitus.  Treatment history was not found to be significantly related to 
presence or absence of CSME. 
  
 
 
 
 
 
Table -5: Severity of Diabetic Retinopathy 
 
Type of DR 
Right Eye Left Eye 
A B A B 
No. % No. % No. % No. % 
No DR 4 8 9 18 10 20 10 20 
Mild NPDR 14 28 20 40 16 32 26 52 
Moderate NPDR 16 32 13 26 12 24 8 16 
Severe NPDR 7 14 3 6 4 8 2 4 
PDR 7 14 3 6 4 8 2 4 
Total 50 100 50 100 50 100 50 100 
 
 Majority of the patients with CSME had moderate NPDR whereas 
patients without CSME had a higher percentage of mild NPDR in either or 
both eyes. 
Table -6: Clinically significant macular edema 
 
CSME 
Right Eye Left Eye 
A B A B 
No. % No. % No. % No. % 
Yes 37 74 0 0 33 66 0 0 
No 13 26 50 100 17 34 50 100 
 
 Among the patients who had CSME, it was more common in right 
eye in our study at 74% than in left eye.  
 
 B: Relationship between Lipid Profile and incidence of CSME in 
patients with Diabetic Retinopathy 
 
Table -7: Total cholesterol and CSME 
Total Cholesterol Group A  Group B   
No. Percentage No. Percentage 
Normal (<200) 13 26 37 74 
Abnormal (>200) 37 74 13 26 
Range 
Mean 
SD 
140 – 516 
268.6 
82.0 
114 – 408 
193.5 
71.2 
P 0.0001 Significant 
 
Total cholesterol levels in patients of Group A ranged from 140 – 
516 mg/dl with a mean of 268.6 mg / dl and Group B from 114 – 408 mg / 
dl with a mean of 193.5 mg / dl.  Total cholesterol level was found to be 
statistically significant with a ‘p’ value of 0.0001. 
 
 
 
  
Table -8: TGL and CSME 
TGL Group A Group B 
No. Percentage No. Percentage 
Normal (< 160) 18 36 31 62 
Abnormal (>160) 32 64 19 38 
Range 
Mean 
SD 
           98 – 318 
173.9 
40.8 
76 – 341 
149.2 
47.3 
P 0.0013  Significant 
 
 Patients with CSME were found to have higher triglyceride levels 
with a mean of 173.9 mg / dl compared to patients without CSME who had 
a mean triglyceride levels of 149.2 mg/dl with the ‘p’ value of 0.0013, 
increased triglyceride levels were found to be significantly related to 
presence of CSME. 
 
 
 
 
  
 
Table -9: HDL and CSME 
HDL Group A Group B 
No. Percentage No. Percentage 
Normal (< 35) 17 34 32 64 
Abnormal (>35) 33 66 18 36 
Range 
Mean 
SD 
12 – 56 
29.5 
8.5 
20 – 44  
34.4 
6.2 
P 0.0007  Significant 
 
 Patients in group A had mean HDL-C levels of 29.5 mg/dl and 
group B of 34.4 mg / dl. Decreased serum HDL-C level was found to 
be significantly related to the presence of CSME. 
 
 
 
 
  
 
Table -10: LDL  and CSME 
LDL Group A Group B 
No. Percentage No. Percentage 
Normal (< 160) 16 32 38 76 
Abnormal (>160) 34 68 12 24 
Range 
Mean 
SD 
84  - 402  
187.2 
62.5 
54 – 300  
119.5 
54.3 
P 0.0001  Significant 
 
 Patients in group A had higher serum LDL-C levels with a mean of 
187.2 mg / dl compared to patients in group B with 119.5 mg% which was 
found to be statistically significant. 
 
 
 
 
 
  
Table -11: VLDL and CSME 
VLDL Group A Group B 
No. Percentage No. Percentage 
Normal (< 40) 20 40 39 78 
Abnormal (>40) 30 60 11 22 
Range 
Mean 
SD 
16 – 110  
51.9 
24.9 
9 – 130  
38.6 
22.4 
P 0.0069  Significant 
 
 Patients in both the groups were found to have higher than 
normal levels of serum VLDL-C with Group A having a mean of 51.9 
mg / dl and group B a mean of 38.6 mg / dl which was found to be 
statistically significant. 
 
 
 
 
  
 
Table -12: Blood Urea and CSME 
Blood Urea Group A Group B 
No. Percentage No. Percentage 
Normal (< 40)  23 46 36 72 
Abnormal (>40) 27 54 14 28 
Range 
Mean 
SD 
16 – 64  
41.2 
15.8 
17 – 70 
33.6 
12.4 
P 0.0115  Significant 
 
            Patients with CSME had higher blood urea level compared to 
patients without CSME 
 
 
 
 
 
 
  
 
Table -13: Serum Creatinine and CSME 
Serum Creatinine Group A Group B 
No. Percentage No. Percentage 
Normal (< 1.2) 18 36 33 66 
Abnormal (>1.2) 32 64 17 34 
Range 
Mean 
SD 
0.6 – 4.4 
1.43 
0.7 
0.6 – 4.3 
1.32 
0.89 
P 0.0142  Significant 
 
              Patients with Diabetic retinopathy in general were found to 
have increased serum creatinine levels with mean value being 1.43 
mg/dl and 1.32 mg /dl in group A and group B respectively. 
 
 
 
 
  
 
Table -14: Blood Pressure and CSME 
TGL Group A Group B ‘p’ 
Mean SD Mean SD 
Systolic BP 18 36 31 62 0.0001 
Significant 
Diastolic 
BP 
86 6.9 83.7 8.1 0.051 Not 
significant 
 
 Patients in both the groups had higher than normal systolic BP 
whereas diastolic blood pressure was normal in either group. 
 
 
 
 
 
 
 
 
 
  
 
Table -15: Fasting Blood Sugar and CSME 
 Group A Group B 
No. Percentage No. Percentage 
Normal (< 126) 18 36 30 60 
Abnormal (>126) 32 64 20 40 
Range 
Mean 
SD 
24 – 314  
154.3 
53.0 
43 – 306  
129.3 
50.0 
P 0.0182  Significant 
 
 Patients with CSME had a higher mean fasting blood sugar levels 
than patients without CSME which was found to be statistically significant 
with a ‘p’ value of 0.0182. 
 
 
 
 
 
  
 
Table -16    Abstract 
Parameters Group A Group B ‘p’ 
Normal Abnormal Normal Abnormal 
Total 
cholesterol 
13 37 37 13 0.0001 
Significant
TGL 18 32 31 19 0.0013 
significant
HDL 17 33 32 18 0.0007 
significant
LDL 16 34 38 12 0.0001 
significant
VLDL 20 30 39 11 0.0069 
significant
Blood Urea 23 27 36 14 0.0015 
significant
Serum 
Creatinine 
18 32 33 17 0.00142 
significant
FBS 18 32 30 20 0.0182 
significant
 
 
 
 
DISCUSSION 
 Diabetic retinopathy is one of the leading causes of blindness in 
people aged 20 to 74 years.  Macular edema is the most frequent 
cause of visual impairment in patients with diabetic retinopathy. 
There are several contradictory reports in literature regarding the lipid 
profile in diabetic retinopathy and its relationship with the presence of 
retinal exudates.  There have been many studies done which compare 
the lipid profile in diabetic retinopathy and its relationship with the 
presence of retinal exudates.  But not many studies have been done 
which compare the lipid profile in subjects with and without CSME.  
This study is a comparative study of serum lipid profile in diabetic 
patients with and without CSME. 
 Most of the observations made in this study correlated with the 
world literature.  Several studies in the past have suggested that the 
prevalence of diabetic retinopathy increases with duration of diabetes 
mellitus. Only 12-16% of the newly detected diabetes in our study 
showed diabetic retinopathy changes.  Most of it was mild NPDR and 
present in only one eye.  The presence of diabetic retinopathy changes 
in newly detected diabetics could also be attributed to late detection 
of diabetes mellitus in our population.  About 42% of patients with 
CSME had diabetes for more than 10 yrs compared to 8% of the 
patients without CSME.  The significance of duration of diabetes is 
evident from the fact that it correlated very well with the presence of 
CSME (p=0.0002).  It had a good negative predictive value in patients 
with less than 10 years of diabetes mellitus. 
 The age and sex distribution was not found to be significant in 
our study with a ‘p’ value of 0.6762 and 0.8415 respectively.  Data 
from the WESDR has shown clearly that duration of diabetes mellitus 
is more important factor for the development of CSME and diabetic 
retinopathy than the age of onset of diabetes. 
 The relationship of glucose control and severity of diabetic 
retinopathy has been studied extensively in observational studies.  
These studies all demonstrated that increased severity of diabetic 
retinopathy is associated with poorer blood glucose control.  Our 
study showed that both patients with and without CSME had higher 
than normal fasting blood glucose levels.  This observation is in 
concurrence with the Diabetes Control and Complications Trial and 
Early Treatment Diabetic Retinopathy Study which showed tight that 
blood glucose control with intensive insulin or conventional treatment 
was associated with a decreased risk of either the development or 
progression of diabetic retinopathy.  In the United Kingdom 
prospective Diabetes study (UKPDS) the largest and longest study of 
patients with type 2 diabetes, there was a 25% reduction in the 
progression of diabetic retinopathy in the intensive treatment group 
compared to the conventional treatment group.  Among the patients 
with diabetic retinopathy, it was found that patients with CSME had a 
higher mean blood sugar levels at 154.3 mg/dl compared to patients 
without CSME. With a ‘p’ value of 0.0182, it is clear that higher 
fasting blood glucose levels are significantly associated with presence 
of CSME.  Our study also showed that there was not much difference 
in the risk of developing CSME among the patients who were on 
treatment compared to those who were not on treatment.  Since most 
of our patients were referred to us from Diabetology department for 
review, they were found to be on some kind of treatment for diabetes, 
either in the form of oral anti hyperglycemic drugs or insulin.  But 
despite treatment, most patients did not have adequate blood glucose 
control.  It showed that they need more frequent tests for blood 
glucose monitoring and more intensive therapy to achieve 
normoglycemic status. 
 Out of the 200 eyes of 100 patients studied, 89 eyes had 
moderate NPDR or more severe forms of diabetic retinopathy.  54 
(60%) of these eyes had CSME compared to 35 (40%) which did not 
have CSME.  Though it was not found to be statistically significant, it 
is still evident that eyes with CSME had more severe forms of 
diabetic retinopathy. 
 Our study also showed that severity of diabetic retinopathy 
increased with the increased duration of diabetes. This is in 
accordance with previous studies.  In the WESDR, it was found that 
in type 1 diabetes, prevalence of retinopathy was seen in 13% patients 
with less than 5 year duration of diabetes. Proliferative diabetic 
retinopathy was rarely found in this group.  However, the prevalence 
increased as duration of diabetes increased and 90% of patients had 
diabetic retinopathy in patients with duration of 10-15 years and 
approximately 25% of these patients had FDR.  For patients with type 
2 diabetes, 24-40% of patients had diabetic retinopathy with duration 
of less than 5 years with PDR constituting 2% of the total.  These 
rates increased to 53-84% respectively with increased diabetes 
duration of 15 to 19 years.  PDR formed 25% of total patients. 
 A number of recent cross sectional studies suggest that serum 
lipid profile may have a causative role in macular edema.  A study by 
Emily Y. Chew et al, who studied the data from ETDRS, concluded 
that patients with elevated total serum total cholesterol levels and 
serum LDL-c levels had two times increased risk to have retinal hard 
exudates than patients who have normal levels. 
 Our study showed that patients with CSME had significantly 
elevated total cholesterol levels at a mean of 268.6 mg/dl.  Patients 
without CSME had slightly lower levels but it was in the high normal 
range.  The difference between the two was statistically significant 
(p=0.0001).  But these results are in contrast with a study done by 
Klein R et al who inferred that there was no relationship between total 
cholesterol and severity of hard exudates in type 2 diabetes that did 
not use insulin though there was a treated for increasing severity of 
diabetic retinopathy and retinal hard exudates with increasing 
cholesterol levels in type 1 diabetes. 
 A study done by S.P. Dhir, Rajvir Dahiya et al in North India 
about Serum Lipoprotein cholesterol profile in diabetic retinopathy 
showed that there was no significant difference though all the values 
were slightly elevated in diabetic retinopathy group.  But study done 
by Macoli F, Odello G et al clearly showed that there was an increase 
in serum total cholesterol levels in patients with exudative 
maculopathy in type 1 diabetes patients. 
 Higher than normal levels of serum triglyceride levels were 
found in patients with CSME in our study compared to patients 
without CSME.  This is in concordance with the study done by Brown 
GC et al who demonstrated higher level of triglyceride in patients 
with exudative maculopathy compared to patients without exudative 
maculopathy.  However, the serum total cholesterol levels was not 
significantly difference among the two groups.  A recent study done 
in Chennai by Rama M, Srivastava BK et al concluded that there is a 
significant association of serum triglyceride with diabetic retinopathy 
but there was no significant association with diabetic macular edema. 
 The same study found that there was significant association of 
serum LDL cholesterol with diabetic macular edema.  This finding is 
supported by our study which showed 68% of patients with CSME 
had abnormal levels of serum LDL-c level compared to only 24% of 
patients without CSME. Significant association of LDL-c levels with 
CSME is also evident with CSME is also evident in the ETDRS 
which showed that higher baseline total and LDL-C levels increased 
the risk of retinal hard exudates formation by two times.  It also 
showed that these patients had an increased risk of visual loss by 50% 
compared with patients with normal levels. Studies by Mohan R et al 
and Dornanth et al have also showed that increase in serum LDL C 
levels is associated with increased risk of maculopathy. 
 A study done by Timethy JL. et al on a subclass in DCCT / 
EDIC cohort, concluded that severity of retinopathy was positively 
associated with triglyceride and VLDL levels and negatively 
associated with HDL-C levels. Our study showed that 60% of patients 
with CSME had increased serum VLDL –C levels compared to 22% 
patients without CSME.  Similarly, 66% of patients in Group A had 
lower than normal HDL – C levels as against 36% patients in Group 
This finding supports the study by Lopes Virella et al who observed a 
inverse correlation between HDL-C and poorly controlled diabetic 
retinopathy.  But a recent study done in Turkey by Ozer PA et al 
found no correlation between serum lipid levels and macular edema, 
but the duration of diabetes was demonstrated as a significant factor 
in the progression of macular edema. They also found a high HbA1C 
levels in all the patients which highlighted the importance of intense 
glycemic control. 
 Our study also showed that patients with CSME had increased 
renal parameters in the form of high levels of blood urea and serum 
creatinine. Patients with CSME also showed higher systolic blood 
pressure although diastolic blood pressure was not found be 
significantly different among the two group.  This is in accordance to 
the previous studies which showed that systemic hypertension and 
renal disease were associated with progression of diabetic 
retinopathy.  But there have not been any studies linking renal disease 
and systemic hypertension to presence or absence or severity of 
macular edema.  Further evaluation is needed in this regard. 
                               
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 The study “Comparative study of Serum Lipid Profile in 
patients with diabetic retinopathy with and without clinically 
significant macular edema” was a case control study of 100 patients 
with diabetic retinopathy at Ophthalmology department of 
Government Rajaji Hospital, Madurai. 
 
 Patients who satisfied the inclusion criteria were interviewed 
regarding the duration of diabetes mellitus and treatment history.  
Fundus examination was done using direct ophthlmoscopy, indirect 
ophthalmoscopy, slip lamp biomicroscopy with +90D lens and fundus 
photographs were taken. Systolic and diastolic blood pressure was 
recorded.  They underwent investigations like, FBS, serum lipid 
profile, blood urea and serum creatinine levels.  The above said 
variables were compared between the two groups. 
 
 There was no significant difference in Age and Sex distribution 
between the two groups.  The present study showed that there were 
significantly higher levels of fasting blood sugars, serum lipids, blood 
urea and serum creatinine among the patients with CSME compared 
to those without CSME.  Both the groups were found to have higher 
systolic blood pressure levels but it was significantly increased in 
patients with CSME.  Diastolic blood pressure was found to be within 
normal range both the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 
The present study clearly shows that there is significant 
correlation between higher levels of serum total cholesterol, LDL-C, 
VLDL-C and triglycerides and presence of clinically significant 
macular edema. 
CSME is also associated with presence of renal disease and 
hypertension.   
The presence of exudative maculopathy is not currently an 
indication for institution of lipid lowering therapy.  Recent advances 
in lipid lowering therapy have presented us with the opportunity to 
intervene effectively in dyslipidemias. While improving 
antihyperglycemic and anti hypertensive therapy is likely to reduce 
the incidence of maculopathy, reducing the progression of exudative 
maculopathy to severe visual loss must also be considered a priority 
and lipid lowering therapy has the potential to augment losses. 
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PROFORMA 
Serial No.  : 
Name :    Age  :  Sex   : 
OP. No. : 
Duration of DM : 
On Treatment      : 
Stage of DR :  RE   LE 
No  DR 
Mild NPDR 
Moderate  NPDR 
Severe NPDR 
PDR 
CSME   RE   LE 
Investigations : 
1. Fasting blood sugar (mg/dl) 
2. Serum lipid profile 
a. Total cholesterol  (mg / dl) 
b. Triglycerides (mg / dl) 
c. LDL – C (mg / dl) 
d. VLDL – C (mg / dl) 
e. HDL – C (mg / dl) 
3. Blood Urea (mg / dl) 
4. Serum creatinine (mg / dl) 
Systolic Blood pressure 
Diastolic Blood pressure 
 
  
 
ABBREVIATIONS 
 
DM DIABETES MELLITUS 
DR DIABETIC RETINOPATHY 
NPDR NON PROLIFERATIVE DIABETIC RETINOPATHY 
PDR PROLIFERATIVE DIABETIC RETINOPATHY 
CSME CLINICALLY SIGNIFICANT MACULAR EDEMA 
DME DIABETIC MACULAR EDEMA 
LDL LOW DENSITY LIPOPROTEIN 
VLDL VERY LOW DENSITY LIPOPROTEIN 
HDL HIGH DENSITY LIPOPROTEIN 
TG TRIGLYCERIDE 
FBS FASTING BLOOD SUGAR 
ETDRS EARLY TREATMENT DIABETIC RETINOPATHY STUDY 
DCCT DIABETICS CONTROL AND COMPLICATIONS TRIAL 
UKPDS UNITED KINGDOM PROSPECTIVE DIABETES STUDY 
WESDR WISCONSIN EPIDEMIOLOGIC STUDY OF DIABETIC 
RETINOPATHY 
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SERUM LIPID PROFILE OF PAITENTS WITH DIABETIC RETINOAPTHY WITH CSME
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RE LE RE LE
1 pethiammal 54 F 413246 7 Y MILD NPDR MOD. NPDR N Y 244 186 20 196 18 26 0.7 134 80 216
2 sarathy 64 M 414241 15 Y SEV NPDR PDR Y Y 414 214 26 348 40 70 3.2 150 96 284
3 kandasamy 44 M 414443 3 Y MOD. NPDR MOD. NPDR Y Y 196 174 14 154 28 32 0.9 120 76 119
4 dhanam 53 F 414819 ND N MILD NPDR NO DR Y N 289 168 40 201 48 21 1.1 130 80 181
5 jayaram 54 M 414624 ND N NO DR MOD. NPDR N Y 200 140 38 140 22 77 1.6 134 90 159
6 natarajan 60 M 414496 20 Y PDR MOD. NPDR Y Y 516 318 34 402 70 84 4.4 160 100 299
7 peer mohammed 68 M 414781 4 Y MOD. NPDR SEV NPDR N Y 140 123 12 122 16 19 1.2 136 76 112
8 rajammal 60 F 415612 11 Y MILD NPDR MILD NPDR Y Y 263 160 30 192 41 24 1.1 140 90 173
9 kathiresan 47 M 415723 13 Y NO DR MOD. NPDR N Y 164 144 35 110 19 44 1.2 154 90 134
10 maniammal 48 F 415946 4.5 Y MOD. NPDR MILD NPDR Y N 211 161 22 140 49 36 1 144 86 126
11 rajangam 51 M 416112 ND N MILD NPDR SEV NPDR Y Y 319 169 31 220 68 51 1.3 140 80 130
12 vellathai 65 F 416114 11 Y MOD. NPDR MOD. NPDR Y Y 160 140 35 90 45 23 0.9 150 84 103
13 muthukani 75 F 416239 12 N PDR SEV NPDR Y Y 418 183 26 308 84 60 1.9 146 90 184
14 chinnan 53 M 415314 ND N MILD NPDR NO DR Y N 324 167 41 219 64 48 1.4 150 84 126
15 shanmugavel 87 M 416491 5 Y MILD NPDR MILD NPDR Y N 281 157 28 193 60 40 1.3 148 90 116
16 ganesan 60 M 416423 1 Y MOD. NPDR NO DR Y N 190 130 30 130 30 27 1.1 140 84 108
17 selvaraj 73 M 416562 11 N MOD. NPDR MOD. NPDR Y Y 223 183 35 161 27 30 1.2 136 90 113
18 mary thomas 56 F 416621 4 Y MILD NPDR SEV NPDR Y Y 216 116 30 143 43 48 1.6 140 86 130
19 sandanam 49 M 416316 18 Y MOD. NPDR PDR Y Y 329 172 23 196 110 40 0.9 126 90 111
20 papammal 60 F 416813 6 Y MOD. NPDR MILD NPDR N Y 194 113 20 148 36 23 0.8 130 90 130
21 pandi 48 M 416916 2 Y MILD NPDR MILD NPDR N Y 442 243 38 300 104 46 1.3 140 84 116
22 gomathi 65 F 416844 1.5 N SEV NPDR MOD. NPDR N Y 346 176 56 212 78 21 1.1 146 80 149
23 pitchai 58 M 416992 ND N MILD NPDR NO DR Y N 288 193 36 196 56 48 1.4 150 80 164
24 angammal 61 F 417231 17 Y SEV NPDR SEV NPDR Y Y 140 98 35 88 17 52 2.2 150 88 214
25 radha 57 F 417255 13 Y MOD. NPDR MILD NPDR Y Y 312 165 42 200 70 31 2 148 90 226
26 singaram 68 F 417367 8 Y MOD. NPDR NO DR Y N 194 143 26 150 18 21 0.8 130 94 126
27 sethulakshmi 65 F 417379 12 Y PDR MILD NPDR Y N 263 193 19 184 60 40 1.4 140 90 140
28 palanisamy 52 M 417413 9 Y MILD NPDR MILD NPDR N Y 299 174 19 211 69 36 1.2 130 80 182
29 chidambaram 71 M 417546 12 Y MOD. NPDR MILD NPDR Y Y 306 148 22 194 90 48 2.6 144 90 314
 STAGE OF DR          CSME
30 thangammal 60 F 417845 16 Y SEV NPDR MILD NPDR Y N 193 136 35 120 38 26 1.2 130 80 148
31 parameswari 57 F 418211 22 Y PDR PDR Y Y 391 204 39 281 71 34 2.4 140 90 284
32 venugopal 54 M 418348 ND N MILD NPDR NO DR Y N 248 167 22 166 60 16 0.8 130 76 128
33 muniyandi 80 M 418446 11 N MOD. NPDR MILD NPDR Y N 144 140 35 84 25 40 1.3 126 80 140
34 balakrishnan 70 M 418325 35 Y PDR SEV NPDR Y Y 206 216 25 160 21 38 0.9 120 70 116
35 shanmugam 63 M 418416 10 Y SEV NPDR MILD NPDR Y N 218 161 24 164 30 37 1.2 140 80 84
36 alagu 62 M 418449 7 Y MOD. NPDR MOD. NPDR Y N 311 148 28 191 82 51 2.1 140 90 186
37 chandrasekar 55 M 418514 6 Y MILD NPDR MILD NPDR Y Y 385 264 36 269 80 70 2.6 138 86 164
38 kalimuthu 44 M 418566 3 Y MILD NPDR NO DR Y N 304 211 40 180 84 36 0.7 160 90 148
39 beevi jaan 66 F 418914 12 Y MOD. NPDR MOD. NPDR Y Y 216 254 24 166 30 49 1.2 148 90 136
40 rakku 60 F 418726 5 Y NO DR MILD NPDR N Y 180 113 30 130 20 20 0.6 130 82 104
41 rajammal 39 F 418839 21 Y PDR SEV NPDR Y Y 251 180 27 184 40 64 1.4 170 100 180
42 subramaniam 60 M 418214 8 Y SEV NPDR NO DR Y N 266 191 31 166 69 60 1.1 140 90 108
43 arokya mary 65 F 418865 11 Y MILD NPDR SEV NPDR N Y 199 142 30 140 25 31 0.9 120 70 116
44 ponnuthai 50 F 418931 1 Y NO DR MILD NPDR N Y 284 186 28 174 82 42 1.2 140 84 130
45 pushpavalli 54 F 418954 6 Y MOD. NPDR MILD NPDR N Y 318 200 44 221 53 48 1.6 150 90 211
46 ranganathan 48 M 419027 3.5 N MOD. NPDR NO DR Y N 277 193 23 194 60 50 1.3 130 80 140
47 rasuthevar 64 M 414621 9 Y SEV NPDR PDR Y Y 254 187 30 171 53 31 0.9 134 80 124
48 backiyam 72 F 419669 15 Y MOD. NPDR MOD. NPDR N Y 316 213 22 214 80 44 1.4 150 90 140
49 gandhimathi 74 F 419734 13 Y PDR MOD. NPDR Y Y 289 160 17 199 73 49 1.6 160 100 136
50 parvathy 60 F 419876 2 Y MOD. NPDR NO DR Y N 301 178 21 240 40 58 2.2 140 94 108
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1 vetrivel 57 M 416521 7 Y MILD NPDR MILD NPDR N N 192 197 42 111 39 21 1.1 120 80 180
2 ganesan 75 M 414461 4 Y MOD. NPDR MILD NPDR N N 142 156 38 83 21 40 1.3 130 84 126
3 karuppayee 55 F 413288 1 Y NO DR MILD NPDR N N 124 117 40 66 18 33 0.9 124 80 141
4 chinnavelu 65 M 415161 ND N MILD NPDR NO DR N N 185 173 35 104 46 24 0.8 134 86 118
5 irulayee 54 F 416613 0.5 Y MILD NPDR MILD NPDR N N 144 132 40 71 33 28 1 110 70 143
6 subbaiah 70 M 416824 12 Y SEV NPDR MOD. NPDR N N 204 146 32 140 32 17 0.7 114 78 189
7 maideen beevi 60 F 416913 1.5 Y MILD NPDR MILD NPDR N N 196 173 20 145 31 23 0.9 120 82 214
8 sethukannan 62 M 417244 2 Y MOD. NPDR MILD NPDR N N 155 146 35 82 28 36 1.2 124 82 116
9 chandra 58 F 417153 20 Y SEV NPDR PDR N N 183 167 40 114 29 40 1.4 130 80 173
10 krishnan 67 M 417355 1 Y NO DR MILD NPDR N N 147 138 30 90 27 26 0.9 130 86 114
11 solamalai 45 M 417426 10 Y SEV NPDR MILD NPDR N N 316 261 30 169 62 18 0.7 140 88 81
12 masilamani 52 M 417538 3 Y MILD NPDR MILD NPDR N N 182 165 40 102 40 32 1 134 82 76
13 senthilmaran 61 M 417612 ND N MILD NPDR NO DR N N 156 148 40 84 32 19 1 124 84 104
14 thangammal 68 F 417677 4 Y MILD NPDR MOD. NPDR N N 214 193 30 165 29 44 1.6 130 80 119
15 rajeshwari 42 F 417813 ND N MILD NPDR MILD NPDR N N 163 165 36 82 45 24 1 116 70 65
16 krishnamoorthy 58 F 417968 ND N MOD. NPDR NO DR N N 174 143 41 93 40 29 0.8 120 80 124
17 annakili 47 F 418114 2.5 Y NO DR MILD NPDR N N 116 97 40 54 22 36 0.9 130 90 142
18 nallathambi 61 M 418134 5 Y SEV NPDR MOD. NPDR N N 408 341 31 300 77 63 4.3 170 100 88
19 annamalai 72 M 418251 1 Y MILD NPDR MILD NPDR N N 158 153 44 74 40 21 0.8 140 90 83
20 sathayi 58 F 418299 1 N MOD. NPDR MILD NPDR N N 143 133 40 70 33 24 0.8 130 80 112
21 kaliammal 50 F 418316 2 N NO DR MILD NPDR N N 151 126 35 81 35 32 0.7 134 84 130
22 chinnathambi 70 M 418422 4 Y MOD. NPDR MOD. NPDR N N 284 214 30 198 56 43 2.1 140 100 172
23 jeyalatha 49 F 418483 3 Y MILD NPDR MOD. NPDR N N 177 168 36 110 31 36 0.9 120 80 118
24 annakodi 56 M 418517 1 N NO DR MILD NPDR N N 164 143 35 103 26 24 1.2 124 80 122
25 karuppaiah 59 M 418584 0.5 N MOD. NPDR MILD NPDR N N 183 162 40 116 27 25 1.1 130 86 124
26 saraswathi 65 F 418615 7 Y MOD. NPDR SEV NPDR N N 310 211 30 204 66 51 4 160 100 306
27 chellammal 62 F 418692 2 Y NO DR MILD NPDR N N 180 165 40 101 39 29 1.1 118 82 118
28 shanthi 53 F 418738 1 N MILD NPDR NO DR N N 137 113 40 56 42 34 0.8 120 84 51
29 venkatesan 56 M 418783 3 Y MILD NPDR MOD. NPDR N N 145 126 42 78 25 19 0.9 130 86 43
 STAGE OF DR          CSME
30 manjaiah 77 M 418816 15 Y PDR SEV NPDR N N 348 166 35 224 89 49 3.3 140 90 132
31 sornamma 70 F 418936 17 Y PDR PDR N N 233 168 22 179 31 36 1.1 130 80 48
32 kalavathi 51 F 418999 1 Y MILD NPDR MILD NPDR N N 174 132 38 106 30 38 1.2 114 70 71
33 muthupetchi 56 F 419000 6 Y SEV NPDR MILD NPDR N N 214 160 30 168 26 28 0.9 140 80 114
34 pethammal 50 F 419002 2 N MILD NPDR MILD NPDR N N 196 114 42 120 34 40 1.1 136 80 211
35 kuruvamma 59 F 419124 ND N MILD NPDR NO DR N N 184 126 37 122 25 33 1.2 114 70 126
36 ramasamy 68 M 419361 9 Y MOD. NPDR NO DR N N 316 148 30 194 82 48 1.4 120 76 146
37 michael john 63 M 429473 3 Y NO DR MILD NPDR N N 114 104 35 60 9 26 0.8 130 86 65
38 kannan 56 M 419636 5 Y MILD NPDR MOD. NPDR N N 156 124 39 108 24 18 0.6 124 80 84
39 pandiammal 64 F 419715 1.5 Y MILD NPDR NO DR N N 148 118 30 82 36 24 0.9 130 90 128
40 bagyalakshmi 48 F 419777 ND N NO DR MILD NPDR N N 129 84 28 68 33 36 0.9 120 80 106
41 muthammal 55 F 419818 0.5 Y MOD. NPDR MILD NPDR N N 143 93 35 74 34 42 1.4 124 90 112
42 vasantha 53 F 419863 2 Y MILD NPDR MILD NPDR N N 246 170 20 201 25 54 2.4 130 74 130
43 sayeeda begum 60 F 419934 9 Y PDR MOD. NPDR N N 400 212 30 240 130 70 4.3 140 100 184
44 veerakalai 64 M 419985 5 N MOD. NPDR SEV NPDR N N 312 194 24 190 98 63 2.6 170 106 126
45 thalaimalai 60 M 420017 1 Y MOD. NPDR NO DR N N 134 76 35 84 25 29 1.1 140 90 214
46 ottammal 63 F 420164 3 Y MOD. NPDR SEV NPDR N N 116 101 23 73 20 32 1 120 80 114
47 kasimayan 59 M 420178 ND N MILD NPDR NO DR N N 188 112 40 121 27 48 1.2 140 94 143
48 mahalingam 53 M 420344 1 Y MILD NPDR MILD NPDR N N 163 83 24 108 31 33 0.8 134 80 189
49 nagarathinam 55 F 420561 2 Y MOD. NPDR NO DR N N 148 99 36 83 29 24 0.8 130 80 209
50 mookan 48 M 420715 ND N NO DR MILD NPDR N N 180 104 35 124 21 19 0.9 126 76 120
